Published on: August 12, 2020 at 09:30PM
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting
https://ift.tt/3fTWMJk
Wednesday, 12 August 2020
New diabetes clinical trial: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Nothing happens without a Reason
Make Something out of it.